trending Market Intelligence /marketintelligence/en/news-insights/trending/ZlCNVCB3UqTlM4WhfBx53w2 content esgSubNav
In This List

PhaseRx to restructure, reduce workforce by 50%

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PhaseRx to restructure, reduce workforce by 50%

PhaseRx, Inc. terminated the employment of its Chief Scientific Officer Michael Houston as part of a restructuring to manage short-term costs.

The company is reviewing strategic options for the business, including a merger transaction, and delaying development of PRX-OTC, its ornithine transcarbamylase deficiency drug.

The company will also lay off 10 employees, including some executive officers. PhaseRx had 20 employees as of June 30, as well as $8.4 million in cash and equivalents.

The reduction will result in a one-time cost of between $411,000 and $426,000 to the company.